相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study
Atul Deodhar et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Understanding the paradigm of non-radiographic axial spondyloarthritis
Diego Benavent et al.
CLINICAL RHEUMATOLOGY (2021)
Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis
Boni E. Elewski et al.
JAMA DERMATOLOGY (2021)
The role of ixekizumab in non-radiographic axial spondyloarthritis
Bon San Koo et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2021)
Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
Xenofon Baraliakos et al.
RHEUMATOLOGY AND THERAPY (2021)
Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial
James Cheng-Chung Wei et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
SECUKINUMAB RETENTION AND SAFETY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS OR ANKYLOSING SPONDYLITIS: 2 YEAR INTERIM RESULTS OF THE OBSERVATIONAL SERENA STUDY
U. Kiltz et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS)
Xenofon Baraliakos et al.
CLINICAL DRUG INVESTIGATION (2020)
Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J)
Mitsumasa Kishimoto et al.
MODERN RHEUMATOLOGY (2020)
Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study
Uta Kiltz et al.
ADVANCES IN THERAPY (2020)
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
Desiree van der Heijde et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Outcomes and treatment responses, including work productivity, among people with axial spondyloarthritis living in urban and rural areas: a mixed-methods study within a national register
Rosemary J. Hollick et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Non-radiographic versus radiographic axSpA: what's in a name?
Xabier Michelena et al.
RHEUMATOLOGY (2020)
Achilles tendon enthesitis evaluated by MRI assessments in patients with axial spondyloarthritis and psoriatic arthritis: a report of the methodology of the ACHILLES trial
Xenofon Baraliakos et al.
BMC MUSCULOSKELETAL DISORDERS (2020)
Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1
Jui-Cheng Tseng et al.
FRONTIERS IN IMMUNOLOGY (2020)
The impact of extra-musculoskeletal manifestations on disease activity, functional status, and treatment patterns in patients with axial spondyloarthritis: results from a nationwide population-based study
Imke Redeker et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2020)
Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5
Feng Huang et al.
CHINESE MEDICAL JOURNAL (2020)
SECUKINUMAB PROVIDES SIGNIFICANT IMPROVEMENT OF SPINAL PAIN IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE 24-WEEK PHASE 3 SKIPPAIN STUDY
D. Poddubnyy et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
IMPACT OF HLA-B27 STATUS ON CLINICAL OUTCOMES AMONG PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH SECUKINUMAB
A. Deodhar et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
SECUKINUMAB DEMONSTRATES A CONSISTENT SAFETY PROFILE IN PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS OVER LONG TERM: UPDATED POOLED SAFETY ANALYSES
A. Deodhar et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviews
Rikke A. Andreasen et al.
ARTHRITIS RESEARCH & THERAPY (2020)
Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study
Karel Pavelka et al.
ACR OPEN RHEUMATOLOGY (2020)
Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials
Stefan Schreiber et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
The European Map of Axial Spondyloarthritis: Capturing the Patient Perspectivean Analysis of 2846 Patients Across 13 Countries
Marco Garrido-Cumbrera et al.
CURRENT RHEUMATOLOGY REPORTS (2019)
Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis
Yoshiya Tanaka et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies
Dennis G. McGonagle et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts
Anne Boel et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
Michael M. Ward et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study
Juergen Braun et al.
RHEUMATOLOGY (2019)
Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the Gap
Atul Deodhar et al.
RHEUMATOLOGY AND THERAPY (2019)
Targeting inflammatory pathways in axial spondyloarthritis
Daniel E. Furst et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?
Fabrizio Cantini et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Spinal radiographic progression over 2years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison
J. Braun et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis
Clementina Lopez-Medina et al.
RMD OPEN (2019)
Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis
Uta Kiltz et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Radiographic progression in non-radiographic axial spondyloarthritis
Mikhail Protopopov et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2018)
Optimizing outcomes for ankylosing spondylitis and axial spondyloarthritis patients: a holistic approach to care
Jonathan Packham
RHEUMATOLOGY (2018)
The current standard of care and the unmet needs for axial spondyloarthritis
Basil Noureldin et al.
RHEUMATOLOGY (2018)
Characterization of Patients With Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis in the US-Based Corrona Registry
Philip J. Mease et al.
ARTHRITIS CARE & RESEARCH (2018)
An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis
Anthony So et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2018)
The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond
Nicolo Costantino Brembilla et al.
FRONTIERS IN IMMUNOLOGY (2018)
Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician
Lawrence Blonde et al.
ADVANCES IN THERAPY (2018)
Sacroiliitis - early diagnosis is key
Gleb Slobodin et al.
JOURNAL OF INFLAMMATION RESEARCH (2018)
Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life
Maike Imkamp et al.
RMD OPEN (2018)
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study
Alan J. Kivitz et al.
RHEUMATOLOGY AND THERAPY (2018)
Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study
Joachim Sieper et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
Juergen Braun et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Non-radiographic axial spondyloarthritis patients without initial evidence of inflammation may develop objective inflammation over time
Xenofon Baraliakos et al.
RHEUMATOLOGY (2017)
Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3
Karel Pavelka et al.
ARTHRITIS RESEARCH & THERAPY (2017)
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
Desiree van der Heijde et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study
Anna Molto et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Secukinumab (AIN457) in the treatment of ankylosing spondylitis
Juergen Braun et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate
Paul Emery et al.
RHEUMATOLOGY (2016)
Which aspects of health are most important for patients with spondyloarthritis? A Best Worst Scaling based on the ASAS Health Index
Uta Kiltz et al.
RHEUMATOLOGY (2016)
SECUKINUMAB REDUCES SACROILIAC JOINT AND SPINAL INFLAMMATION IN PATIENTS WITH ANKYLOSING SPONDYLITIS: MRI DATA FROM A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (MEASURE 1)
X. Baraliakos et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
SECUKINUMAB IMPROVES MULTIPLE PARAMETERS OF DISEASE ACTIVITY IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS THROUGH 52 WEEKS OF SUBCUTANEOUS THERAPY: DATA FROM THE PHASE 3 MEASURE 2 STUDY
J. Braun et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Dominique Baeten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Clinical Tools to Assess and Monitor Spondyloarthritis
Robert Landewe et al.
CURRENT RHEUMATOLOGY REPORTS (2015)
Calculating the Ankylosing Spondylitis Disease Activity Score If the Conventional C-Reactive Protein Level Is Below the Limit of Detection or If High-Sensitivity C-Reactive Protein Is Used: An Analysis in the DESIR Cohort
Pedro Machado et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Targeting IL-17and TH17 cells in chronic inflammation
Pierre Miossec et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?
Uta Kiltz et al.
ARTHRITIS CARE & RESEARCH (2012)
Measures of Symptoms and Disease Status in Ankylosing Spondylitis Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQOL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S)
Jane Zochling
ARTHRITIS CARE & RESEARCH (2011)
Clinical significance of inflammatory back pain for diagnosis and screening of patients with axial spondyloarthritis
Juergen Braun et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Anti-TNF therapy in ankylosing spondylitis: insights for the clinician
Laura C. Coates et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2010)
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal
M. Rudwaleit et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis
LC Doward et al.
ANNALS OF THE RHEUMATIC DISEASES (2003)
分享论文
